About: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 14 August 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2006 (fr) наукова стаття, опублікована в серпні 2006 (uk) scientific article published on 14 August 2006 (en) artículu científicu espublizáu n'agostu de 2006 (ast)
publication date	wds:Q80112164-27CC0BC8-837C-41CF-8EF1-92B6109E0AB4
publication date	2006-08-14 00:00:00Z (xsd:dateTime)
author name string	wds:Q80112164-22123398-A1A5-4653-9788-0D575D948B61 wds:Q80112164-37893FE9-53AD-4903-B24C-799B6294C9D8 wds:Q80112164-5B088EE1-D1A7-4471-AAC5-B60ED892BB6B wds:Q80112164-7FF69292-7A60-4B2A-8CBB-3E43BA75C230 wds:Q80112164-D9A42329-B511-4C0B-A51A-52A7783B71A5 wds:Q80112164-DC0FB6AF-92C8-4E9C-A8A1-CDA5FF533707 wds:Q80112164-F0CB9046-3E91-41FA-9D4B-13AB54712546
author name string	Gabriel N Hortobagyi Vicente Valero Kenneth R Hess Jean-Bernard Durand Daniel J Lenihan Kristine Broglio Laura Boehnke Michaud
rdfs:label	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (en) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (nl)
skos:prefLabel	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (en) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (nl)
name	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (en) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (nl)
author	wds:Q80112164-2CC955DC-20DF-429C-956E-884AD6095162 wds:Q80112164-A174EFBD-BE02-49D7-9DFE-0233268E162C wds:Q80112164-C89BAE44-659E-4F1A-BD89-BD1FD565E7EB
author	Valentina Guarneri Ana Maria Gonzalez-Angulo Francisco J Esteva
title	wds:Q80112164-3648306A-7C98-4CB4-8E5A-C11C6548B5B5
title	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience (en)
page(s)	wds:Q80112164-B4EC3D07-0C79-4057-860F-6E92A8504A8E
page(s)	4107-4115
instance of	wds:Q80112164-538DB6D1-FB5D-4D31-BFEC-6A9A9A2B2A0C
instance of	scholarly article
main subject	wds:Q80112164-49BDADA7-D716-451B-AAF1-83FE8BD2C255 wds:Q80112164-BCB31DAA-0CC3-4571-B2FE-25CC2FBC9A5F
main subject	trastuzumab metastatic breast cancer
PubMed ID	wds:Q80112164-15ED8FAB-5111-4809-9D00-334DE70D2A95
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16908934
PubMed ID	16908934
published in	wds:Q80112164-83E4EFD1-D681-4D5D-A012-A0FD3FF4D3D1
published in	Journal of Clinical Oncology
issue	wds:Q80112164-D8D6EFDF-E652-4B09-AF73-82540CAC5B03
volume	wds:Q80112164-0231E6D7-EEB9-498E-B18C-154F5E8A8DE6
issue	25
volume	24
DOI	wds:Q80112164-AD720FC0-3011-48C1-A82E-A4D072463FD5
DOI	http://dx.doi.org/10.1200/JCO.2005.04.9551
DOI	10.1200/JCO.2005.04.9551
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q80112164
is cites work of	Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab Drug-induced cardiovascular disorders Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model CNS complications of breast cancer: current and emerging treatment options Cardiovascular toxicity of molecularly targeted agents. Novel biomarkers in chronic heart failure Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial Targeting HER2 in breast cancer: overview of long-term experience Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction. Neuregulin-1/ErbB signaling and chronic heart failure Cardio-oncology/onco-cardiology. Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience Lapatinib. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes Cardiovascular complications of breast cancer therapy in older adults Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines Computational analyses of curcuminoid analogs against kinase domain of HER2 Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors Trastuzumab-related cardiotoxicity among older patients with breast cancer Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Cardiotoxicity of anticancer treatments Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools Chemotherapy-induced cardiomyopathy Trastuzumab in the management of early and advanced stage breast cancer. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software